These subjects were then followed up for an average of 30 months until they developed DLB (MCI-DLB group) or AD (MCI-AD group), based on clinical evaluation (and dopamine transporter imaging for DLB). The gene discussed is SLC6A3; the disease is Alzheimer disease.